Cancer Pain - Pipeline Review, H2 2017

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or Email: pdb@bioportfolio.co.uk
Cancer Pain - Pipeline Review, H2 2017

Cancer Pain - Pipeline Review, H2 2017

Summary


Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic and neurosurgical pain management.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Pain - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 5, 5, 22, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Cancer Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Cancer Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Cancer Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Cancer Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Pain (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Cancer Pain (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Cancer Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Additional Details

**Publisher**: Global Markets Direct  
**Reference**: GMDHC9856IDB  
**Number of Pages**: 125  
**Report Format**: PDF  
**Publisher Information**: 
Table Of Contents for Cancer Pain - Pipeline Review, H2 2017 [Report Updated: 31-10-2017]

- Table of Contents
- Table of Lists of Tables
- List of Figures
- Introduction
- Global Markets Direct Report
- Coverages
- Cancer Pain - Overview
- 7Cancer Pain - Therapeutics Development
- 8Pipeline Overview
- 8Pipeline by Companies
- 9Pipeline by Universities/Institutes
- 13Products under Development
- by Companies
- 14Products under Development
- by Universities/Institutes
- 17Cancer Pain - Therapeutics Assessment
- 18Assessment by Target
- 18Assessment by Mechanism of Action
- 21Assessment by Route of Administration
- 24Assessment by Molecule Type
- 26Cancer Pain - Companies Involved in Therapeutics Development
- 28Alexza Pharmaceuticals
- 28AngioChem Inc
- 28Aoxing Pharmaceutical Company Inc
- 28Aphios Corp
- 29AstraZeneca Plc
- 29ChironWells GmbH
- 30Colby Pharmaceutical Co
- 30ConSyrnance Therapeutics Inc
- 30Daewoong Pharmaceutical Co Ltd
- 31Daichi Sankyo Co Ltd
- 31Dome Pharmaceutical Co SpA
- 32Fujimoto Pharmaceutical Corp
- 32Grunenthal GmbH
- 33Hisamitsu Pharmaceutical Co Inc
- 33Immupharma Plc
- 33Insys Therapeutics Inc
- 34IntelGenx Corp
- 34iX Biopharma Ltd
- 35Klaria Pharma Holding AB
- 35Komipharm International Co Ltd
- 36KPI Therapeutics Inc
- 36Medlab Clinical Ltd
- 37Nanomerics Ltd
- 37Neurocentrx Pharma Ltd
- 37Nippon Kayaku Co Ltd
- 38Orion Corporation
- 38Pain Therapeutics Inc
- 39Pfizer Inc
- 39Pharmaceuticals
- SA
- 40Recordati SpA
- 40Ribomic Inc
- 41Trillium Therapeutics Inc
- 41Virobay Inc
- 42WEX Pharmaceuticals Inc
- 42Cancer Pain - Drug Profiles
- 43(fentanyl + menthol) - Drug Profile
- 43(fentanyl + naloxone) - Drug Profile
- 44ANG-2002 - Drug Profile
- 45AQU-118 - Drug Profile
- 46AZD-8797 - Drug Profile
- 47Cannabis Intractable - Drug Profile
- 49cebranopadol - Drug Profile
- 50CPC-111 - Drug Profile
- 54crotalaphine - Drug Profile
- 55CSTI-200 - Drug Profile
- 56dexmedetomidine hydrochloride - Drug Profile
- 57dronabinol - Drug Profile
- 60Drug for Cancer Neuropathic Pain - Drug Profile
- 61DWJ-208 - Drug Profile
- 62fentanyl - Drug Profile
- 63fentanyl citrate - Drug Profile
- 64fentanyl citrate ER - Drug Profile
- 66gabapentin - Drug Profile
- 67HP-3150 - Drug Profile
- 68HS-198 - Drug Profile
- 69hydromorphone hydrochloride - Drug Profile
- 70HYLP-002 - Drug Profile
- 71INT-0010 - Drug Profile
- 72IPP-102199 - Drug Profile
- 73KL-00406 - Drug Profile
- 74KL-006 - Drug Profile
- 75methadone hydrochloride - Drug Profile
- 76Monoclonal Antibodies to Inhibit TRPV1 for Inflammatory Pain and Cancer Pain - Drug Profile
- 77NM-127 - Drug Profile
- 78PAX-1 - Drug Profile
- 79Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous System - Drug Profile
- 80Peptide to Target CANP for Cardiovascular and Cancer Pain - Drug Profile
- 81PL-265 - Drug Profile
- 82PL-37 - Drug Profile
- 84QX-314 - Drug Profile
- 86RBM-004 - Drug Profile
- 87RBM-007 - Drug Profile
- 88resiniferatoxin - Drug Profile
- 89saracatinib difumarate - Drug Profile
- 91Sallmall Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
- 93Sallmall Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
- 94Sallmall Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
- 95Tanezumab - Drug Profile
- 96Tetrotodotoxin - Drug Profile
- 100Tildine hydrochloride - Drug Profile
- 102TOT-303 - Drug Profile
- 103U-2902 - Drug Profile
- 104VBY-825 - Drug Profile
- 106zucapsaicin - Drug Profile
- 107Cancer Pain - Dormant Projects
- 109Cancer Pain - Discontinued Products
- 112Cancer Pain - Product Development Milestones
- 113Featured News & Press Releases
- 113Appendix
- 120Methodology
- 120Coverage
- 120Secondary Research
- 120Primary Research
- 120Expert Panel Validation
- 120Contact Us
- 120Disclaimer
- 121
How to Buy...


Option 1 - Online
Go to our website and pay online with any major debit or credit card:
https://www.bioportfolio.co.uk/product/139723

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at pdb@bioportfolio.co.uk or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: ..................................................................................................................................................
Job Title: ......................................................................................................................................................
Your Email: ...................................................................................................................................................
Your Contact Phone: .....................................................................................................................................
Company Name: ..............................................................................................................................................
Address: ........................................................................................................................................................
Post/Zip Code: ................................................................................................................................................
Country: ..........................................................................................................................................................
P.O. Number: ..................................................................................................................................................
Any Other Instructions: ......................................................................................................................................

Pricing Options: (please tick one)
☐ ££££;2000 | Single User Price
☐ ££££;4000 | Site License Price
☐ ££££;6000 | Enterprise License Price

Payment Options: (please tick one)
☐ Online Credit Card (we will email you the invoice with a payment link)
☐ Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature: ........................................................................................................................................

Option 3 - Phone Us on +44 (0)7887 945155
We will be delighted to give you our personal attention.